Table Info

Table 1.

Characteristics of patients

Characteristics	Baseline	Year 1	Year 5	Year 6	Year 7	Year 8	Year 9	Year 10
Patients, n	74	74	74	41	32	18	11	8
Age (year) mean [standard deviation (SD)]	51.3 (11)	51.3 (11)	51.3 (11)	50.6 (11.1)	50.5 (10.2)	50.7 (6.8)	52.3 (7.3)	52 (8.5)
Female, n (%)	45 (60.8)	45 (60.8)	45 (60.8)	26 (63.4)	22 (68.8)	12 (66.7)	7 (63.6)	6 (75)
Male, n (%)	29 (39.2)	29 (39.2)	29 (39.2)	15 (36.6)	10 (31.3)	6 (33.3)	4 (36.4)	2 (25)
Weight (kg), mean (SD)	76.3 (13.1)	76.3 (13.1)	76.3 (13.1)	77.5 (14.2)	76.6 (13.5)	73.7 (11.2)	75.6 (10.8)	71.6 (9.9)
BMI (kg/m²)	26.3	26.3	26.3	26.7	26.4	25.4	26	25.9
Smoking status, n (%)
Never, n (%)	47 (63.5)	47 (63.5)	47 (63.5)	28 (68.3)	22 (68.8)	14 (77.8)	9 (81.8)	6 (75)
Current, n (%)	5 (6.8)	5 (6.8)	5 (6.8)	3 (7.3)	3 (9.4)	0 (0)	0 (0)	0 (0)
Previous, n (%)	22 (29.7)	22 (29.7)	22 (29.7)	10 (24.4)	7 (21.9)	4 (22.2)	2 (18.2)	2 (25)
Use of oral corticosteroids (OCSs)
Patients, n	44	44	44	26	22	12	7	5
OCS (mg), mean (SD)	20.9 (21.3)	5 (7.2)	3.9 (6.3)	5 (9.1)	6.5 (12.9)	4.2 (4.8)	5.4 (6.3)	6.5 (5.4)

Declarations

Acknowledgments

We thank our patients for their contribution and willingness to use their data in the manuscript.

Author contributions

KCB: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. TH and KS: Writing—review & editing. SK: Data Curation, Formal analysis, Visualization. TZ: Writing—review & editing, Supervision.

Conflicts of interest

Karl-Christian Bergmann and Torsten Zuberbier who are the Associate Editors of Exploration of Asthma & Allergy had no involvement in the decision-making or the review process of this manuscript. KCB gives lectures at ALK, AstraZeneca, Bencard, Berlin-Chemie, GSK, HAL, Leti, Sanofi, Stallergenes. TZ reports industry consulting, research grants and/or honoraria from AImmune, Ajanta Pharma, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bayer Health Care, Bencard, Berlin Chemie, Bio Cryst, Celldex, FAES, HAL, Henkel, Kryolan, Leti, Lofarma, L’Oreal, Meda, Medi Wound, Menarini, Merck, MMV Medicines for Malaria Venture, MSD, Novartis, PCM Scientific, Pfizer, Sanofi, Sanoflore, Stallergenes, Takeda, Teva, and UCB. He is a member of the Initiative “Allergic Rhinitis and its Impact on Asthma” (ARIA), Member of the Board for German Society for Allergy and Clinical Immunology (DGAKI), Chairman of the Board of European Centre for Allergy Research Foundation (ECARF), President of Global Allergy and Asthma European Network (GA2LEN), and member of Committee on Allergy Diagnosis and Molecular Allergology for World Allergy Organisation (WAO). All other authors declare no conflicts of interest.

Ethical approval

The monocentric study was approved by the Charité ethics committee (permit number EA 1/098/18) and complied with the Declaration of Helsinki.

Consent to participate

Informed consent to participate was obtained from relevant participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservations, to any qualified researcher.

Funding

Exploration and statistic evaluation of data was financially supported by Novartis GmbH, Germany. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med. 2023;33:7. [DOI] [PubMed] [PMC]

Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy. 2004;59:701–8. [DOI] [PubMed]

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–90. [DOI] [PubMed]

Papaioannou AI, Mplizou M, Porpodis K, Fouka E, Zervas E, Samitas K, et al. Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. Allergy Asthma Proc. 2021;42:235–42. [DOI] [PubMed]

Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, et al. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. J Allergy Clin Immunol Pract. 2021;9:2702–14. [DOI] [PubMed]

Schreiber J, Schwab Sauerbeck I, Mailänder C. The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study. Adv Ther. 2020;37:353–63. [DOI] [PubMed]

Huang WC, Fu PK, Chan MC, Chin CS, Huang WN, Lai KL, et al. The Long-Term Effectiveness of Omalizumab in Adult Patients with Severe Allergic Asthma: Continuous Treatment Versus Boosting Treatment. J Clin Med. 2021;10:707. [DOI] [PubMed] [PMC]

Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J. 1999;14:23–7. [DOI] [PubMed]

Pennock BE, Rogers RM, McCaffree DR. Changes in measured spirometric indices. What is significant? Chest. 1981;80:97–9. [DOI] [PubMed]

10.

Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. [DOI] [PubMed]

11.

Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65. [DOI] [PubMed]

12.

Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124:719–23.e1. [DOI] [PubMed]

13.

Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–61. [DOI]

14.

Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–9. [DOI] [PubMed]

15.

Akenroye AT, Segal JB, Zhou G, Foer D, Li L, Alexander GC, et al. Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023;151:1269–76. [DOI] [PubMed] [PMC]

16.

Domingo C, Mirapeix RM, González-Barcala FJ, Forné C, García F. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study. Drugs. 2023;83:1111–23. [DOI] [PubMed]

17.

Hanania NA, Niven R, Chanez P, Antoine D, Pfister P, Garcia Conde L, et al. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. World Allergy Organ J. 2022;15:100695. [DOI] [PubMed] [PMC]

18.

Gemicioğlu B, Çalışkaner Öztürk B, Duman B. Comparison of allergic asthma patients treated with omalizumab and non-allergic patients treated with continuous oral corticosteroids: results of five year follow-up therapies. Tuberk Toraks. 2016;64:97–104. [DOI] [PubMed]

19.

Pace E, Ferraro M, Bruno A, Chiappara G, Bousquet J, Gjomarkaj M. Clinical benefits of 7 years of treatment with omalizumab in severe uncontrolled asthmatics. J Asthma. 2011;48:387–92. [DOI] [PubMed]